Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Omnibus Outcomes
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
    • Research Compliance
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • 2024 Solicitation
    • Application Process
    • Entering Portfolio
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Peptilogics

Peptilogics, Pittsburgh, USA
www.peptilogics.com

PLG0206
NOVEL CLASS OF DIRECT-ACTING ENGINEERED PEPTIDES

Antibiotic
Peptilogics is developing unique engineered peptide-based antibiotics to address difficult-to-treat infections, including those caused by or containing a bacterial biofilm component associated with prosthetic joint infections (PJI). The lead compound, PLG0206, is a broad-spectrum agent with activity against the critical ESKAPE pathogens, with an initial focus on the predominant causative agents found in wound, surgical site, and implant-associated infections. The CARB-X award will support the development of PLG0206 including the filing of a US FDA Investigational New Drug Application, leading to a Phase 1 clinical study in patients. Peptilogics’ program has been granted Qualified Infectious Disease Product (QIDP) status and Orphan Drug Designation by the FDA.

The number of knee, hip and other joint replacements around the world is growing every year. In the US alone, more than 1 million total joint replacements are performed annually, a number expected to grow to 4 million by 2030.

Current Development Stage: Phase 1

CARB-X Investment: Initial investment of up to $2.56m with potential option payments up to $9.61m.

Initial CARB-X Investment Date: January 1, 2020

Read the Spotlight feature about Peptilogics.

Carb-X

Led by Boston University

Copyright 2025

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2025

We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent